• Citer

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

par Spira, Alexander;Awada, Ahmad ;Isambert, Nicolas;Lorente, David;Penel, Nicolas;Zhang, Hong-Yue;Ojalvo, Laureen;Hicking, Christine;Rolfe, Alexander P.A.;Ihling, Christian;Dussault, Isabelle;Locke, George;Borel, Christian
Référence Frontiers in oncology, 12, 981940
Publication Publié, 2022-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer
Auteur:	Spira, Alexander; Awada, Ahmad; Isambert, Nicolas; Lorente, David; Penel, Nicolas; Zhang, Hong-Yue; Ojalvo, Laureen; Hicking, Christine; Rolfe, Alexander P.A.; Ihling, Christian; Dussault, Isabelle; Locke, George; Borel, Christian
Informations sur la publication:	Frontiers in oncology, 12, 981940
Statut de publication:	Publié, 2022-12
Sujet CREF:	Cancérologie
Mots-clés:	bintrafusp alfa
	PD-L1
	TGF-β
	triple-negative breast cancer
	tumor microenvironment
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2234-943X
	info:doi/10.3389/fonc.2022.981940
	info:scp/85144985275